Sept 24 (Reuters) - Endo International PLC ENDP.O :
* ENDO AGREES TO ADDITIONAL STAY OF FDA LITIGATION FOLLOWING FDA'S COMMITMENT TO USE BEST EFFORTS TO FINALIZE VASOPRESSIN CLINICAL NEED DETERMINATION BY YEAR END
* ENDO INTERNATIONAL PLC - AGREED TO AN ADDITIONAL STAY OF ITS LITIGATION AGAINST U.S. FDA UNTIL DECEMBER 31, 2018
* ENDO INTERNATIONAL PLC - ENDO AGREED TO PROPOSED STAY AND PARTIES JOINTLY MOVED COURT FOR APPROVAL ON SEPT 21, 2018
* ENDO INTERNATIONAL SAYS MOTION WAS UNOPPOSED BY INTERVENOR OUTSOURCING FACILITY
* ENDO INTERNATIONAL - IF COURT APPROVES PROPOSED STAY CO'S MOTION FOR PRELIM INJUNCTION TO BE HELD IN ABEYANCE
* ENDO INTERNATIONAL PLC - REITERATES PRIOR STATEMENT THAT BULK COMPOUNDING OF VASOPRESSIN BY OUTSOURCING FACILITIES IS "INAPPROPRIATE"
* ENDO INTERNATIONAL - HEARING ON MOTION FOR PRELIM INJUNCTION CURRENTLY SCHEDULED FOR OCTOBER 3, 2018 WILL BE TAKEN OFF CALENDAR